These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7674597)

  • 1. TGF-beta: a cytokine mediator of glomerulosclerosis and a target for therapeutic intervention.
    Border WA; Noble NA; Ketteler M
    Kidney Int Suppl; 1995 Jun; 49():S59-61. PubMed ID: 7674597
    [No Abstract]   [Full Text] [Related]  

  • 2. [Transforming growth factor-beta: a new approach to the pathogenesis of glomerulonephritis and glomerulosclerosis].
    Witowski J; Knapowski J
    Przegl Lek; 1995; 52(9):467-73. PubMed ID: 8834649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor-beta and the glomerular extracellular matrix in renal pathology.
    Bruijn JA; Roos A; de Geus B; de Heer E
    J Lab Clin Med; 1994 Jan; 123(1):34-47. PubMed ID: 8288959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanism of Chinese herbal medicine delaying progression of chronic kidney disease].
    Dou C; Wan Y; Sun W; Zhagn H; Chen J; Shui G; Yao J
    Zhongguo Zhong Yao Za Zhi; 2009 Apr; 34(8):939-43. PubMed ID: 19639770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [TGF-beta: usage in nephrology].
    Quirin N; Feige JJ; Zaoui P
    Nephrologie; 1996; 17(4):227-35. PubMed ID: 8768454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney.
    Isaka Y; Fujiwara Y; Ueda N; Kaneda Y; Kamada T; Imai E
    J Clin Invest; 1993 Dec; 92(6):2597-601. PubMed ID: 8254017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of blocking renin-angiotensin system on the progression of renal injury in glomerulosclerosis.
    Ji Z; Huang C; Liang C; Chen B; Chen S; Sun W
    Cell Mol Immunol; 2005 Apr; 2(2):150-4. PubMed ID: 16191423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement.
    Kelly B; Petitt M; Sanchez R
    J Am Acad Dermatol; 2008 Jun; 58(6):1025-30. PubMed ID: 18485985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Receptors and functions of TGF-beta, a crucial cytokine in wound healing].
    García-Sainz JA; Vilchis-Landeros MM; Juárez P; López-Casillas F; Hernández-Pando R; Massagué J
    Gac Med Mex; 2003; 139(2):126-43. PubMed ID: 12754948
    [No Abstract]   [Full Text] [Related]  

  • 10. Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target?
    Noble NA; Border WA
    Semin Nephrol; 1997 Sep; 17(5):455-66. PubMed ID: 9316214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glomerulosclerosis: the final pathway is clarified, but can we deal with the triggers?
    Wardle N
    Nephron; 1996; 73(1):1-7. PubMed ID: 8742949
    [No Abstract]   [Full Text] [Related]  

  • 12. Notch receptors: a new target in glomerular diseases.
    Mertens PR; Raffetseder U; Rauen T
    Nephrol Dial Transplant; 2008 Sep; 23(9):2743-5. PubMed ID: 18503100
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytokine networks and the pathogenesis of glomerulonephritis.
    Johnson RJ
    J Lab Clin Med; 1993 Feb; 121(2):190-2. PubMed ID: 8433031
    [No Abstract]   [Full Text] [Related]  

  • 14. Glomerulosclerosis: intrinsic and extrinsic pathways.
    El Nahas AM
    Nephrol Dial Transplant; 1996 May; 11(5):773-7. PubMed ID: 8671893
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic targets for prevention and regression of progressive fibrosing renal diseases.
    Eitner F; Floege J
    Curr Opin Investig Drugs; 2005 Mar; 6(3):255-61. PubMed ID: 15816501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The intrarenal renin-angiotensin system: a paracrine system for the local control of renal function separate from the systemic axis.
    Harris RC; Cheng HF
    Exp Nephrol; 1996; 4 Suppl 1():2-7. PubMed ID: 9001891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene transfer and kidney disease.
    Imai E; Isaka Y; Akagi Y; Kaneda Y; Hori M
    J Nephrol; 1998; 11(1):16-9. PubMed ID: 9561480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vasoactive peptides and the development of renal sclerosis: contribution of transgenes].
    Dussaule JC; Boffa JJ; Tharaux PL; Flamant M; Fakhouri F; Chatziantoniou C
    J Soc Biol; 2002; 196(4):275-80. PubMed ID: 12645295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokines and mesangial cells.
    Sterzel RB; Schulze-Lohoff E; Marx M
    Kidney Int Suppl; 1993 Jan; 39():S26-31. PubMed ID: 8468921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of chronic renal allograft dysfunction from evaluations of TGFBeta1 and the renin-angiotensin system.
    Yamada K; Hatakeyama E; Arita S; Sakamoto K; Kashiwabara H; Hamaguchi K
    Clin Exp Nephrol; 2003 Sep; 7(3):238-42. PubMed ID: 14586721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.